IMMUPHARMA PLC — Regulatory Filings 2017

Mar 22, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1863A

Immupharma PLC

22 March 2017

	22 MARCH 2017

NOTIFICATION OF MAJOR INTEREST BY ALTO INVEST

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Alto Invest ("Alto") confirming its holding in ImmuPharma of 5,802,317 million Ordinary Shares in the capital of the Company, representing 4.38% of ImmuPharma's total voting rights figure of  132,522,985 Ordinary Shares.

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Alto's increased holding in ImmuPharma as a further key major institutional investor which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma."

Ends

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLVLLBLDXFZBBK